Certara (NASDAQ:CERT) Sets New 12-Month High – Still a Buy?

Certara, Inc. (NASDAQ:CERT) reached a new 52-week high during mid-day trading on Thursday. The stock traded as high as $12.00 and last traded at $11.17, with a volume of 197,349 shares traded. The stock had previously closed at $11.09.

Analysts Set New Price Targets

CERT has been the subject of a number of analyst reports. KeyCorp lifted their price objective on shares of Certara from $9.00 to $12.00 and gave the company an “overweight” rating in a research report on Friday, October 16th. Weiss Ratings cut shares of Certara from a “sell (d)” rating to a “sell (d-)” rating in a report on Thursday, October 8th. TD Cowen raised their target price on shares of Certara from $9.00 to $11.00 and gave the company a “buy” rating in a research note on Tuesday, October 13th. Barclays lifted their price target on Certara from $7.50 to $9.00 and gave the stock an “equal weight” rating in a report on Wednesday, October 7th. Finally, UBS Group downgraded Certara from a “buy” rating to a “neutral” rating and set a $10.00 price target on the stock. in a research report on Wednesday, September 30th. One equities research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, six have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $9.18.

Certara Stock Up 2.0%

The firm’s 50 day simple moving average is $9.18 and its two-hundred day simple moving average is $7.32. The firm has a market cap of $1.73 billion, a price-to-earnings ratio of -25.24 and a beta of 1.30. The company has a current ratio of 2.55, a quick ratio of 2.55 and a debt-to-equity ratio of 0.30.

Certara (NASDAQ:CERT) last released its quarterly earnings results on Thursday, November 5th. The company reported $0.09 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.09. The company had revenue of $94.90 million during the quarter, compared to the consensus estimate of $92.01 million. Certara had a negative net margin of 16.75% and a positive return on equity of 3.86%. The firm’s quarterly revenue was down 9.3% on a year-over-year basis. During the same period in the previous year, the business earned $0.14 earnings per share. On average, equities analysts forecast that Certara, Inc. will post 0.21 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the company. Fulcrum Asset Management LLP lifted its position in shares of Certara by 341.9% during the 3rd quarter. Fulcrum Asset Management LLP now owns 63,508 shares of the company’s stock worth $588,000 after buying an additional 49,138 shares during the last quarter. Childress Capital Advisors LLC grew its position in Certara by 85.8% in the third quarter. Childress Capital Advisors LLC now owns 24,221 shares of the company’s stock valued at $223,000 after acquiring an additional 11,186 shares during the last quarter. North Star Investment Management Corp. bought a new position in shares of Certara in the third quarter worth about $800,000. GAMMA Investing LLC grew its holdings in shares of Certara by 21.2% during the 3rd quarter. GAMMA Investing LLC now owns 9,778 shares of the company’s stock valued at $90,000 after purchasing an additional 1,710 shares during the last quarter. Finally, Sequoia Financial Advisors LLC increased its position in Certara by 12.0% during the 2nd quarter. Sequoia Financial Advisors LLC now owns 17,906 shares of the company’s stock worth $117,000 after purchasing an additional 1,923 shares in the last quarter. 73.96% of the stock is owned by institutional investors.

Certara Company Profile

Certara is a global provider of software and services that support drug development and regulatory approval. The company helps biopharmaceutical and pharmaceutical organizations use quantitative methods, modeling and simulation, and regulatory science to improve decisions throughout the development process.

Its software portfolio includes platforms for pharmacometric modeling and simulation, clinical trial design and analysis, pharmacology and safety assessment, data visualization, and regulatory submission management.